HSIC icon

Henry Schein

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 46.7%
Negative

Positive
Zacks Investment Research
18 hours ago
Why Henry Schein (HSIC) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Henry Schein (HSIC) is a Top Growth Stock for the Long-Term
Positive
The Street
5 days ago
Amazon Stock Is Underrated — And These 4 Picks Are Too
The AI trade is moving beyond Big Tech — and Ari Sass has the hidden value stocks Wall Street hasn't caught up to yet.
Amazon Stock Is Underrated — And These 4 Picks Are Too
Neutral
Business Wire
6 days ago
Henry Schein to Reduce Size of the Board of Directors following 2026 Annual Meeting of Stockholders
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, today announced its plan to reduce the size of its Board of Directors following its 2026 Annual Meeting of Stockholders on May 21, 2026. Stanley M. Bergman is to retire from the Board after 44 years as a director of Henry Schein. In recognition of Mr. Bergman's leadership and the significant contributions he has made to the Co.
Henry Schein to Reduce Size of the Board of Directors following 2026 Annual Meeting of Stockholders
Positive
Barrons
7 days ago
Williams, Henry Schein, and 3 Other Bargain Stocks From a Veteran Value Fund Manager
Ari Sass of the M.D. Sass Concentrated Value ETF is hunting for reasonably priced growth stocks like Henry Schein.
Williams, Henry Schein, and 3 Other Bargain Stocks From a Veteran Value Fund Manager
Positive
Zacks Investment Research
14 days ago
Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term
Negative
Zacks Investment Research
19 days ago
Henry Schein (HSIC) Down 9.4% Since Last Earnings Report: Can It Rebound?
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock?
Henry Schein (HSIC) Down 9.4% Since Last Earnings Report: Can It Rebound?
Negative
Zacks Investment Research
19 days ago
Should You Retain Henry Schein Stock in Your Portfolio for Now?
HSIC's growth from its Henry Schein One venture and partnerships is promising, but macro pressures and stiff competition raise concerns for investors.
Should You Retain Henry Schein Stock in Your Portfolio for Now?
Positive
Zacks Investment Research
27 days ago
Here's Why Henry Schein (HSIC) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Henry Schein (HSIC) is a Strong Growth Stock
Neutral
Business Wire
27 days ago
Ethisphere Names Henry Schein as One of the 2026 World's Most Ethical Companies® for 15th Consecutive Year
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, has been recognized as one of the 2026 World's Most Ethical Companies® by Ethisphere, a global leader in defining and advancing the standards of ethical business practices. “To be honored for our ethical practices reflects the values that have guided Henry Schein for decades,” said Fred M. Lowery, Chief Executive Officer of He.
Ethisphere Names Henry Schein as One of the 2026 World's Most Ethical Companies® for 15th Consecutive Year
Positive
Seeking Alpha
1 month ago
Henry Schein: Still A Buy - But Caution Is Warranted
Henry Schein, Inc. is rated a 'Buy' as signs of improving growth and undervaluation emerge despite recent stagnation. HSIC's recent results show solid revenue and EPS growth, but operating margins and ROIC remain pressured, challenging its economic moat. Management guides for 3–5% sales growth and 5–8% non-GAAP EPS growth in 2026, supported by strategic focus on high-margin businesses and digital transformation.
Henry Schein: Still A Buy - But Caution Is Warranted